Federal regulators Wednesday night gave Genzyme Corp. the go-ahead to sell a new pill to treat multiple sclerosis in the United States.

The positive ruling for the Cambridge biotechnology company’s therapy, called Aubagio, marks the Food and Drug Administration’s first approval of a Genzyme drug since French pharmaceutical giant Sanofi SA bought Genzyme for $20.1 billion in 2010.